Lyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer.
Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 16, 2021 | IPO | $425M | — | — | — | Detail |
Mar 12, 2020 | Series C | $492.99M | — | — | — | Detail |
Oct 10, 2018 | Series A | — | 4 | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Mar 31, 2021
Outpace Bio
|
Series A | $30M | Biotechnology | Yes |
Sep 30, 2020
Sonoma Pharmaceuticals
|
Post-IPO Equity | $70M | Health Care | — |
Sep 30, 2020
Sonoma BioTherapeutics
|
Series A | $30M | Biotechnology | — |
Mar 18, 2020
Cero Therapeutics
|
Series A | $40M | Biotechnology | — |
Mar 17, 2020
Eureka Therapeutics
|
Series E | $45M | Biotechnology | Yes |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Venture Partners | — | Series A |
Arrive | — | Series A |
Bill & Melinda Gates Foundation | — | Series A |
Sahsen Ventures | — | Series A |
Lyell Immunopharma has had 1 exits. Lyell Immunopharma most notable exits include Sonoma Pharmaceuticals
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Jan 25, 2007 | Sonoma Pharmaceuticals | IPO | Health Care | Detail |